The THE RELATIONSHIP OF TUMOUR BUDDING AND TUMOUR INFILTRATING LYMPHOCYTES IN DIAGNOSTIC BREAST CORE BIOPSIES WITH PATHOLOGICAL RESPONSE IN RESECTION SPECIMENS
DOI:
https://doi.org/10.55519/JAMC-S4-13143Keywords:
Tumor budding(TB), Tumor infiltrating lymphocytes(TILs), Breast cancer.Abstract
Background: Breast cancer, ranks as the second-leading global cancer-related cause of death. This article highlights prognostic significance of tumour budding and tumour infiltrating lymphocytes, emphasizing their roles in guiding treatments. Recent discoveries support their pivotal contribution in enhancing risk assessments and refining management strategies in breast cancer. Methods: A retrospective study of 80 in house at Shaukat Khanum Memorial Cancer Hospital diagnosed with invasive ductal carcinoma in the year 2014. Patients were categorized into two groups based on receptor status: Group 1 (ER/PR positive, Her2 negative, or ER/PR/Her2 positive) and Group 2 (Triple negative and ER/PR negative, Her2 positive). Each group had 40 cases. Pathologists evaluated tumour budding, tumour infiltrating lymphocytes, Nottingham Grading, and receptor status on core biopsies. Study aimed to determine the relationship of TB and TILs assessed on core biopsies on corresponding resection specimen in terms of pathological tumour stage and overall survival after therapy. Results: In Group I, TILs >50% correlated with lower pathological tumour stage, while <50% correlated with higher post- treatment tumour stage. In Group II, most had <50% TILs, but some responded well. Low TB-Status in Group I linked to higher rates of ypT0, while in Group II, high TB-Status corresponded with high PT stage, i.e., yPT1 suggesting prognostic value for TILs and TB in breast cancer response and staging. Conclusions: Study suggests that higher TILs percentages correlate with improved treatment response and survival in contrast to lower TILs. Similarly, lower TB-status is associated with complete treatment response (y PT0) and higher TB- status is directly related to poor treatment response and higher tumour stage.References
1) 1: Menhas R, Shumaila UM. Breast cancer among Pakistani women. Iranian journal of public health. 2015 Apr;44(4):586.
2) Aziz Z, Iqbal J, Akram M. Predictive and prognostic factors associated with survival outcomes in patients with stage I-III breast cancer: A report from a developing country. Asia-Pacific Journal of Clinical Oncology. 2008 Jun;4(2):81-90.
3) Voutsadakis IA. Prognostic role of tumor budding in breast cancer. World journal of experimental medicine. 2018 Sep 9;8(2):12.
4) Gujam F, McMillan D, Mohammed Z, Edwards J, Going J. The relationship between tumour budding, the tumour microenvironment and survival in patients with invasive ductal breast cancer. British journal of cancer. 2015;113(7):1066-74.
5) Pagès F, Kirilovsky A, Mlecnik B, Asslaber M, Tosolini M, Bindea G, et al. In situ cytotoxic and memory T cells predict outcome in patients with early-stage colorectal cancer. J Clin Oncol. 2009;27(35):5944-51
6) Dieu-Nosjean MC, Antoine M, Danel C, Heudes D, Wislez M, Poulot V, et al. Long-term survival for patients with non-small-cell lung cancer with intratumoral lymphoid structures. J Clin Oncol. 2008;26(27):4410-7.
7) Denkert C, Loibl S, Noske A, Roller M, Müller BM, Komor M, et al. Tumor-associated lymphocytes as an independent predictor of response to neoadjuvant chemotherapy in breast cancer. J Clin Oncol. 2010;28(1):105-13
8) Goff SL, Danforth DN. The Role of Immune Cells in Breast Tissue and Immunotherapy for the Treatment of Breast Cancer. Clin Breast Cancer. 2021;21(1):e63-e73.
9) Ye F, Dewanjee S, Li Y, Jha NK, Chen ZS, Kumar A, et al. Advancements in clinical aspects of targeted therapy and immunotherapy in breast cancer. Mol Cancer. 2023;22(1):105.
10) Dictionary SsM. Nottingham grading system 2023
11) Oncology ASoC. ESTROGEN AND PROGESTERONE RECEPTOR TESTING IN BREAST CANCER: ASCO/CAP GUIDELINE UPDATE. American Society of Clinical Oncologyhttp://www.asco.org/breast-cancer-guidelines; 2020.
12) Salgado R, Denkert C, Demaria S, Sirtaine N, Klauschen F, Pruneri G, et al. The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014. Ann Oncol. 2015;26(2):259-71.
13) Hendry S, Salgado R, Gevaert T, Russell PA, John T, Thapa B, Christie M, Van De Vijver K, Estrada MV, Gonzalez-Ericsson PI, Sanders M. Assessing tumor infiltrating lymphocytes in solid tumors: a practical review for pathologists and proposal for a standardized method from the International Immuno-Oncology Biomarkers Working Group: Part 2: TILs in melanoma, gastrointestinal tract carcinomas, non-small cell lung carcinoma and mesothelioma, endometrial and ovarian carcinomas, squamous cell carcinoma of the head and neck, genitourinary carcinomas, and primary brain tumors. Advances in anatomic pathology. 2017 Nov;24(6):311.
14) (CAP) CoAP. Protocol for the Examination of Resection Specimens from Patients with Invasive Carcinoma of the Breast 2023 [cited 2023
15) Bianchini G, Gianni L. The immune system and response to HER2-targeted treatment in breast cancer. The Lancet Oncology. 2014 Feb 1;15(2):e58-68.
16) GarcÃa-Teijido P, Cabal ML, Fernández IP, Pérez YF. Tumor-infiltrating lymphocytes in triple negative breast cancer: the future of immune targeting. Clinical Medicine Insights: Oncology. 2016 Jan;10:CMO-S34540.
17) Teramoto H, Koike M, Tanaka C, Yamada S, Nakayama G, Fujii T, Sugimoto H, Fujiwara M, Suzuki Y, Kodera Y. Tumor budding as a useful prognostic marker in T1-stage squamous cell carcinoma of the esophagus. Journal of surgical oncology. 2013 Jul;108(1):42-6.
18) Mitrovic B, Schaeffer DF, Riddell RH, Kirsch R. Tumor budding in colorectal carcinoma: time to take notice. Modern Pathology. 2012 Oct 1;25(10):1315-25.
19) Yamaguchi Y, Ishii G, Kojima M, Yoh K, Otsuka H, Otaki Y, Aokage K, Yanagi S, Nagai K, Nishiwaki Y, Ochiai A. Histopathologic features of the tumor budding in adenocarcinoma of the lung: tumor budding as an index to predict the potential aggressiveness. Journal of thoracic oncology. 2010 Sep 1;5(9):1361-8.
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 Farhana Maryam, Madiha Syed, Maryam Hameed, Sajid Mushtaq, Mudassar Hussain, Kiran Imran
This work is licensed under a Creative Commons Attribution-NoDerivatives 4.0 International License.
Journal of Ayub Medical College, Abbottabad is an OPEN ACCESS JOURNAL which means that all content is FREELY available without charge to all users whether registered with the journal or not. The work published by J Ayub Med Coll Abbottabad is licensed and distributed under the creative commons License CC BY ND Attribution-NoDerivs. Material printed in this journal is OPEN to access, and are FREE for use in academic and research work with proper citation. J Ayub Med Coll Abbottabad accepts only original material for publication with the understanding that except for abstracts, no part of the data has been published or will be submitted for publication elsewhere before appearing in J Ayub Med Coll Abbottabad. The Editorial Board of J Ayub Med Coll Abbottabad makes every effort to ensure the accuracy and authenticity of material printed in J Ayub Med Coll Abbottabad. However, conclusions and statements expressed are views of the authors and do not reflect the opinion/policy of J Ayub Med Coll Abbottabad or the Editorial Board.
USERS are allowed to read, download, copy, distribute, print, search, or link to the full texts of the articles, or use them for any other lawful purpose, without asking prior permission from the publisher or the author. This is in accordance with the BOAI definition of open access.
AUTHORS retain the rights of free downloading/unlimited e-print of full text and sharing/disseminating the article without any restriction, by any means including twitter, scholarly collaboration networks such as ResearchGate, Academia.eu, and social media sites such as Twitter, LinkedIn, Google Scholar and any other professional or academic networking site.
